Laser modestly improved lichen sclerosus symptoms

Carbon dioxide laser improved symptoms more than clobetasol at 3 months in women with vulvar lichen sclerosus.
*Randomized controlled trial; Level 2 (OCEBM).

Citation

Hecken JM, Shoham I, Tempfer CB, Rezniczek GA. Laser Treatment Compared with Topical Clobetasol for Lichen Sclerosus: A Randomized Controlled Trial. Obstet Gynecol. 2026;148:451-461. doi:10.1097/AOG.0000000000006326

Background

Vulvar lichen sclerosus can cause chronic itching, burning, pain, scarring, sexual pain, and reduced quality of life. High-potency topical steroid treatment is standard care, but laser treatment is increasingly used despite limited trial evidence.

Patients

245 adult women with symptomatic vulvar, perineal, or perianal lichen sclerosus. Exclusions included immunosuppressive treatment, prior vulvar cancer, vulvar dysplasia, vulvar surgery, clobetasol contraindication, sunlight allergy, or interfering skin disease.

Intervention

Three low-density fractional carbon dioxide laser treatments, 3 weeks apart.

Control

Clobetasol propionate 0.05% tapered over 3 months.

Outcome

Primary: change in burn-itch-pain score (0-30; lower is better). Secondary: physician-rated improvement and vulvar disease quality of life.

Follow-up Period

Primary endpoint: 3 months; exploratory crossover follow-up: 6 months.

Results

Outcome Laser Clobetasol Effect
Burn-itch-pain change at 3 months (primary) Median -8 Median -5 Adjusted difference -2.90 (95% CI -4.64 to -1.15)
Physician-rated visual improvement Median 6 Median 3.5 Favored laser
Physician-rated overall improvement Median 7 Median 5 Favored laser
Quality-of-life score change Median -7 Median -5 Favored laser

Analyses were intention-to-treat. The prespecified clinically meaningful difference for the burn-itch-pain score was 2 points; the adjusted difference exceeded this. Clobetasol was the current standard treatment. No serious treatment-related adverse events occurred.

Limitations

Open-label, single-center design may exaggerate benefit, especially for symptom-reported outcomes. The primary score was not independently validated. Follow-up was short for a chronic condition, cancer prevention and long-term maintenance effects were not assessed, and results apply only to this specific laser protocol. The absolute symptom difference was modest.

Funding

Institutional funds only; no external funding or reported conflicts.

Clinical Application

Consider carbon dioxide laser as an adjunct, not replacement, for symptomatic patients inadequately controlled with standard clobetasol maintenance.